↓ Skip to main content

Dove Medical Press

Article Metrics

Intravitreal use of bone marrow mononuclear fraction containing CD34+ stem cells in patients with atrophic age-related macular degeneration

Overview of attention for article published in Clinical Ophthalmology, May 2017
Altmetric Badge

About this Attention Score

  • In the top 25% of all research outputs scored by Altmetric
  • Good Attention Score compared to outputs of the same age (77th percentile)
  • High Attention Score compared to outputs of the same age and source (92nd percentile)

Mentioned by

news
1 news outlet

Citations

dimensions_citation
30 Dimensions

Readers on

mendeley
40 Mendeley
Title
Intravitreal use of bone marrow mononuclear fraction containing CD34<sup>+</sup> stem cells in patients with atrophic age-related macular degeneration
Published in
Clinical Ophthalmology, May 2017
DOI 10.2147/opth.s133502
Pubmed ID
Authors

Carina Cotrim, Luiza Toscano, Andre Messias, Rodrigo Jorge, Rubens Siqueira

Abstract

To evaluate the therapeutic potential and safety of intravitreal injections of bone marrow mononuclear fraction (BMMF) containing CD34(+) cells in patients with atrophic age-related macular degeneration (AMD). Ten patients with atrophic AMD and best-corrected visual acuity (BCVA) in the worse-seeing eye of ≤20/100 were enrolled in this study. The bone marrow from all patients was aspirated and processed for mononuclear cell separation. A 0.1 mL suspension of BMMF CD34(+) cells was injected into the vitreous cavity of the worse-seeing eye. Patients were evaluated at Baseline and 1,3,6,9 and 12 months after injection. Ophthalmic evaluation included BCVA measurement, microperimetry, infrared imaging, fundus autofluorescence and SD-optical coherence tomography at all study visits. Fluorescein angiography was performed at Baseline and at 6 and 12 months after intravitreal therapy. All patients completed the 6-month follow-up, and six completed the 12-month follow-up. Prior to the injection, mean BCVA was 1.18 logMAR (20/320(-1)), ranging from 20/125 to 20/640(-2), and improved significantly at every follow-up visit, including the 12-month one, when BCVA was 1.0 logMAR (20/200) (P<0.05). Mean sensitivity threshold also improved significantly at 6, 9 and 12 months after treatment (P<0.05). Considering the area of atrophy identified by fundus autofluorescence, significant mean BCVA and mean sensitivity threshold improvement were observed in patients with the smallest areas of atrophy. Fluorescein angiography did not identify choroidal new vessels or tumor growth. The use of intravitreal BMMF injections in patients with AMD is safe and is associated with significant improvement in BCVA and macular sensitivity threshold. Patients with small areas of atrophy have a better response. The paracrine effect of CD34(+) cells may explain the functional improvement observed; however, larger series of patients are necessary to confirm these preliminary findings.

Mendeley readers

The data shown below were compiled from readership statistics for 40 Mendeley readers of this research output. Click here to see the associated Mendeley record.

Geographical breakdown

Country Count As %
United States 1 3%
Unknown 39 98%

Demographic breakdown

Readers by professional status Count As %
Student > Bachelor 9 23%
Researcher 5 13%
Student > Postgraduate 4 10%
Other 4 10%
Student > Doctoral Student 3 8%
Other 10 25%
Unknown 5 13%
Readers by discipline Count As %
Medicine and Dentistry 18 45%
Biochemistry, Genetics and Molecular Biology 6 15%
Nursing and Health Professions 2 5%
Agricultural and Biological Sciences 2 5%
Neuroscience 2 5%
Other 2 5%
Unknown 8 20%

Attention Score in Context

This research output has an Altmetric Attention Score of 8. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 18 July 2018.
All research outputs
#1,936,578
of 13,243,534 outputs
Outputs from Clinical Ophthalmology
#98
of 1,726 outputs
Outputs of similar age
#48,869
of 218,791 outputs
Outputs of similar age from Clinical Ophthalmology
#1
of 14 outputs
Altmetric has tracked 13,243,534 research outputs across all sources so far. Compared to these this one has done well and is in the 85th percentile: it's in the top 25% of all research outputs ever tracked by Altmetric.
So far Altmetric has tracked 1,726 research outputs from this source. They receive a mean Attention Score of 3.4. This one has done particularly well, scoring higher than 94% of its peers.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 218,791 tracked outputs that were published within six weeks on either side of this one in any source. This one has done well, scoring higher than 77% of its contemporaries.
We're also able to compare this research output to 14 others from the same source and published within six weeks on either side of this one. This one has done particularly well, scoring higher than 92% of its contemporaries.